



Key Indices Update

Indices	Close	Change (%)
Nifty	22552.50	0.03 🗷
Sensex	74332.58	لا 0.01
Midcap	49190.60	ע 0.32
Smallcap	15504.30	0.67 🗷

Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
12	1818 <mark>/1093</mark>

Key Data

Data	Current	Previous
Dow Jones	42,637.5	42,688.5
U.S. Dollar Index	103.68	104.15
Brent Crude (USD/BBL)	70.08	69.60
US 10Y Bond Yield (%)	4.28	4.27
India 10Y Bond Yield (%)	6.75	6.76

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	48447.55	ע 0.37
NIFTYAUTO	21009.6	0.24 7
NIFTYENERGY	31779.05	0.16 7
NIFTYFINSRV	24785.8	ע 0.32
NIFTYFMCG	51861.75	لا 0.06
NIFTYIT	37779.9	لا 0.96
NIFTYMEDIA	1488.15	1.77 7
NIFTYMETAL	8911.9	0.26 🗷
NIFTYPHARMA	20360.75	ע 31.31
NIFTYREALTY	815.9	וב 1.24

MARCH 10, **2025**

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
ICICIBANK	Bank	1,214	1,424	17.3%

*CMP as on Mar. 07, 2025

Top News

- Narayana Hrudayalaya's overseas arm, Health City Cayman Islands, has partnered with 2070 Health, W Health Ventures, and Everhope Oncology to set up cancer treatment centers in India. The 50:50 joint venture plans a USD 10M investment over 1-2 years, focusing on chemotherapy.
- + India Pesticides Limited has signed a Power Purchase and Shareholders Agreement with Fourth Partner Solar Power to enhance renewable energy sources. This agreement will supply renewable energy for 25 years.

Technical

Refer Page 03-04

- + Nifty traded in a narrow range and ended almost flat, pausing after two consecutive sessions of gains.
- + Sectoral movement kept traders engaged, with metals finishing in the green, while realty and IT were among the laggards.
- + Nifty is now approaching its immediate resistance at 22,700 and will require fresh catalysts to break past this level.
- + Given the mixed signals, we recommend maintaining a positive yet cautious stance, with a focus on prudent position sizing.
- + Stock of the day SBICARD.





Fundamental

Top News

01

Narayana Hrudayalaya's overseas arm, Health City Cayman Islands, has partnered with 2070 Health, W Health Ventures, and Everhope Oncology to set up cancer treatment centers in India. The 50:50 joint venture plans a USD 10M investment over 1-2 years, focusing on chemotherapy.

02

India Pesticides Limited has signed a Power Purchase and Shareholders Agreement with Fourth Partner Solar Power to enhance renewable energy sources. This agreement will supply renewable energy for 25 years.

03

IndusInd Bank and Visa launch the DropTheLabel campaign to empower women against societal stereotypes. Featuring chess player Tania Sachdev, it offers exclusive benefits and celebrates women's strength and potential.

04

*Zia Nikhil Sawhney plans to acquire 9,99,705 equity shares of Triveni Turbine Limited from her husband, Nikhil Sawhney, via an off-market inter-se transfer on March 17, 2025.5.

05

*Lemon Tree Hotels Limited has signed two License Agreements for new properties in Madhya Pradesh, managed by Carnation Hotels. Located on the Delhi-Mumbai Expressway, they're set to open in FY 2026, boosting strategic growth in the state.

Stock for Investment

ICICI Bank

Stock Symbol	ICICIBANK
Sector	Bank
*CMP (₹)	1,214
^Target Price (₹)	1,424
Upside	17.3%
*CMP as on Mar. 07, 2025 ^Time horizon - upto 11 Months	

- + ICICI Bank is one the leading private sector bank in India which provides wide range of financial services along with its subsidiaries. It has pan-India presence with 6,600 branches.
- + During Q3FY25, its net interest income increased by 1.6% QoQ/9.1% YoY as the bank saw slight decline in its margins while healthy growth in assets. Advances/deposits increased by 13.9%/14.1% YoY while overall asset quality remained stable, with GNPA/NNPA seeing an improvement by 34bps/2bps QoQ to 1.96%/0.42% due to lesser slippages.
- + The bank margins (NIM's) saw a marginal decline during the quarter by 2bps YoY. The bank expect margin to remain around current levels as the as the cost of deposits peak off and they maintain healthy high yielding asset book.
- + Going forward, its assets quality remains strong due to its strong underwriting framework. It is also better placed to mobilize deposits higher than the industry. The bank aims to make investment in technology, people and distribution.
- + Financially, we expect NII/PPOP/PAT to grow at 9.3%/8.6%8.8% CAGR over FY24-27E and maintain **Buy** with a **target price** of **Rs 1,424.**





Technical

Reached to its immediate hurdle i.e. 20 DEMA. Stay stock-specific.

NIFTY	
22552.50 7 7.80 (0.03%)	

S1	S2	R1	R2
22430	22300	22700	22800

- + Nifty traded in a narrow range and ended almost flat, pausing after two consecutive sessions of gains.
- + Sectoral movement kept traders engaged, with metals finishing in the green, while realty and IT were among the laggards.
- + Nifty is now approaching its immediate resistance at 22,700 and will require fresh catalysts to break past this level.
- + Given the mixed signals, we recommend maintaining a positive yet cautious stance, with a focus on prudent position sizing.

BANKNIFTY	S1	\$2	R1	R2
48497.50 🏻 130.20 (0.27%)	48100	47800	48650	49000



- + The banking index ended lower, taking a breather after three days of advance.
- Among the banking majors, Axisbank and Kotakbank closed in green. While others witnessed profit taking, Indusindbk lost the most.
- + The index may continue to consolidate if it maintains its footing above 48200-47800 support levels, with immediate resistance at 48900-49000 zone.
- + Having said that, a cautious approach, especially in banking index, is necessary until a decisive move is seen.





Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
SBICARD	BUY	834.80	830-835	810	880



- + Sbicard has surged vertically since the beginning of this year, which is from the low of around 660 mark.
- + Currently, the stock is placed near the neckline of the consolidation range, digesting the recent gains.
- + It is soon set to resume its prevailing trend and surpass its swing high.
- Traders can consider to accumulate the stock given the favorable risk-reward ratio.

Momentum Stocks Midcap

Name	Price	Price %
TRITURBINE	609.95	13.85 🗷
SHYAMMETL	825.5	8.86 7
SPARC	134.5	6.70 🗷
BDL	1131.2	6.15 🗷
STLTECH	85.4	5.63 7

Name	Price	Price %	-
ATGL	607.85	2.01 7	Ranc Br
ATUL	5700	1.15 7	nge Breakout/ Breakdown
LUPIN	2029	0.52 7	reak dow
PAYTM	682.6	3.36 كا	'n (î
OFSS	7540	3.64 צ	

- 1
ers
⊆
ō
Ō
0
ŭ
F&C
വ
0
0
H

Name	Price	Price %
TITAGARH	759.00	5.34 7
RELIANCE	1,249.80	3.32 🗷
SRF	2,935.35	2.94 7
APOLLOTYRE	411.70	2.71 🗷
MANAPPURAM	208.39	2.38 7

Name	Price	Price %	- op
KALYANKJIL	431.70	4.15 🗵	δ σ
MGL	1,284.00	3.93 🗵	F&O
ZOMATO	216.83	3.81 🗵	
INDUSINDBK	936.75	3.60 كا	Losers
OFSS	7,569.10	3.27 צו	Ľ

ts	
ō	
등	
ے	
æ	
页	
ш	

Name	Price	Price %
EICHERMOT	5,100.70	0.12 🗷
HINDALCO	691.35	1.38 🗷
MANAPPURAM	208.39	2.38 🗷
NESTLEIND	2,238.45	1.69 🗷
SRF	2,935.35	2.94 🗷

Name	Price	Price %	_
BSE	4,178.30	וא 1.77	Bearish
INDUSINDBK	936.75	3.60 ¥	_
INFY	1,686.00	וו 1.74	Charts
OFSS	7,569.10	צ 3.27	rts
PAYTM	684.85	צ 3.04 צ	





Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.guptal@religare.com





Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]	-	No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest if answer to F(a) above is Yes:	Name(s) with Signature(s) of RA(s)

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results